• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Let's talk Double Down





Ok DT lets have a serious discussion. Very few will make goals on Akynzeo unless something drastic happens.

We are referring to it as the double cross. You won't make your Akynzeo goal so you won't double down but you'll pass on other opportunities with other companies like expansions because you think that this money might actually materialize.